Which has preferable valuation & earnings, ADAG or OCS?

Adagene has higher revenue and earnings than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 22.49 -$17.61M N/A N/A Oculis N/A N/A -$119.44M -$2.13 N/A

Is ADAG or OCS more profitable?

Adagene has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Adagene's return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Oculis -8,460.67% -56.78% -45.62%

Which has preferable earnings & valuation, ADAG or FBRX?

Adagene has higher revenue and earnings than Forte Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 22.49 -$17.61M N/A N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is ADAG or FBRX more profitable?

Adagene's return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Forte Biosciences N/A -106.17% -85.50%

Which has preferable valuation and earnings, ADAG or GYRE?

Gyre Therapeutics has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 22.49 -$17.61M N/A N/A Gyre Therapeutics $116.59M 5.88 $5.03M -$0.09 N/A

Which has preferable earnings and valuation, SPRY or ADAG?

Adagene has lower revenue, but higher earnings than ARS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARS Pharmaceuticals $98.99M 5.34 -$171.30M -$2.01 N/A Adagene $7.67M 22.49 -$17.61M N/A N/A

Which has better valuation and earnings, ALLO or ADAG?

Adagene has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 32,789.25 -$190.89M -$0.77 N/A Adagene $7.67M 22.49 -$17.61M N/A N/A

Is ALLO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Adagene N/A N/A N/A

Adagene (ADAG) Competitors

$3.64 +0.01 (+0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$3.65 +0.01 (+0.27%)

As of 04:10 PM Eastern

Compare

ADAG vs. OCS, FBRX, GYRE, SPRY, and ALLO

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include Oculis (OCS), Forte Biosciences (FBRX), Gyre Therapeutics (GYRE), ARS Pharmaceuticals (SPRY), and Allogene Therapeutics (ALLO).

How does Adagene compare to Oculis?

Adagene (NASDAQ:ADAG) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Adagene has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Adagene has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Adagene's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Oculis	-8,460.67%	-56.78%	-45.62%

9.5% of Adagene shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Adagene presently has a consensus price target of $8.00, indicating a potential upside of 119.78%. Oculis has a consensus price target of $38.33, indicating a potential upside of 219.71%. Given Oculis' higher probable upside, analysts plainly believe Oculis is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Adagene has higher revenue and earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.49	-$17.61M	N/A	N/A
Oculis	N/A	N/A	-$119.44M	-$2.13	N/A

In the previous week, Oculis had 7 more articles in the media than Adagene. MarketBeat recorded 7 mentions for Oculis and 0 mentions for Adagene. Adagene's average media sentiment score of 1.79 beat Oculis' score of 1.07 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Very Positive
Oculis	Positive

Summary

Adagene beats Oculis on 10 of the 14 factors compared between the two stocks.

How does Adagene compare to Forte Biosciences?

Adagene (NASDAQ:ADAG) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Forte Biosciences had 9 more articles in the media than Adagene. MarketBeat recorded 9 mentions for Forte Biosciences and 0 mentions for Adagene. Adagene's average media sentiment score of 1.79 beat Forte Biosciences' score of 0.35 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Very Positive
Forte Biosciences	Neutral

9.5% of Adagene shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adagene currently has a consensus price target of $8.00, indicating a potential upside of 119.78%. Forte Biosciences has a consensus price target of $72.50, indicating a potential downside of 5.30%. Given Adagene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Adagene is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Adagene has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.6, meaning that its share price is 160% more volatile than the broader market.

Adagene's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Forte Biosciences	N/A	-106.17%	-85.50%

Adagene has higher revenue and earnings than Forte Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.49	-$17.61M	N/A	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Summary

Adagene beats Forte Biosciences on 9 of the 12 factors compared between the two stocks.

How does Adagene compare to Gyre Therapeutics?

Adagene (NASDAQ:ADAG) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Adagene has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.49	-$17.61M	N/A	N/A
Gyre Therapeutics	$116.59M	5.88	$5.03M	-$0.09	N/A

Adagene currently has a consensus price target of $8.00, suggesting a potential upside of 119.78%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 176.42%. Given Gyre Therapeutics' higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

9.5% of Adagene shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Adagene has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Adagene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, Gyre Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Gyre Therapeutics and 0 mentions for Adagene. Adagene's average media sentiment score of 1.79 beat Gyre Therapeutics' score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Very Positive
Gyre Therapeutics	Neutral

Summary

Gyre Therapeutics beats Adagene on 8 of the 14 factors compared between the two stocks.

How does Adagene compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Adagene has lower revenue, but higher earnings than ARS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	5.34	-$171.30M	-$2.01	N/A
Adagene	$7.67M	22.49	-$17.61M	N/A	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ARS Pharmaceuticals presently has a consensus price target of $28.20, indicating a potential upside of 430.08%. Adagene has a consensus price target of $8.00, indicating a potential upside of 119.78%. Given ARS Pharmaceuticals' higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Adagene's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Adagene	N/A	N/A	N/A

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Adagene. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 0 mentions for Adagene. Adagene's average media sentiment score of 1.79 beat ARS Pharmaceuticals' score of 0.70 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
ARS Pharmaceuticals	Positive
Adagene	Very Positive

ARS Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Adagene beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Adagene compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Adagene	N/A	N/A	N/A

Adagene has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,789.25	-$190.89M	-$0.77	N/A
Adagene	$7.67M	22.49	-$17.61M	N/A	N/A

In the previous week, Allogene Therapeutics had 6 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Allogene Therapeutics and 0 mentions for Adagene. Adagene's average media sentiment score of 1.79 beat Allogene Therapeutics' score of 0.32 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Neutral
Adagene	Very Positive

Allogene Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 348.54%. Adagene has a consensus target price of $8.00, indicating a potential upside of 119.78%. Given Allogene Therapeutics' higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Adagene beats Allogene Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$172.50M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	N/A	7.35	279.73	25.56
Price / Sales	22.49	1,275.27	649.61	116.36
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	4.85	17.09	11.12	6.36
Net Income	-$17.61M	-$12.52M	$3.48B	$347.58M
7 Day Performance	-2.41%	2.63%	2.67%	3.24%
1 Month Performance	-18.57%	-5.27%	-2.70%	-2.00%
1 Year Performance	86.76%	51.48%	64.43%	21.31%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.7077 of 5 stars	$3.64 +0.3%	$8.00 +119.8%	+89.1%	$172.50M	$7.67M	N/A	260	Positive News
OCS Oculis	3.4576 of 5 stars	$11.96 +2.0%	$38.33 +220.5%	-32.8%	$680.16M	$1.45M	N/A	2	News Coverage Positive News Upcoming Earnings
FBRX Forte Biosciences	1.2719 of 5 stars	$50.73 +6.8%	$68.75 +35.5%	+697.2%	$659.45M	N/A	N/A	5
GYRE Gyre Therapeutics	1.6969 of 5 stars	$6.06 +3.1%	$17.00 +180.5%	-8.1%	$655.55M	$116.59M	N/A	40	News Coverage Positive News Upcoming Earnings
SPRY ARS Pharmaceuticals	2.5488 of 5 stars	$6.36 -1.2%	$28.20 +343.4%	-68.2%	$639.51M	$84.28M	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. OCS, FBRX, GYRE, SPRY, and ALLO

How does Adagene compare to Oculis?

Summary

How does Adagene compare to Forte Biosciences?

Summary

How does Adagene compare to Gyre Therapeutics?

Summary

How does Adagene compare to ARS Pharmaceuticals?

Summary

How does Adagene compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. OCS, FBRX, GYRE, SPRY, and ALLO

How does Adagene compare to Oculis?

Which has more volatility & risk, ADAG or OCS?

Is ADAG or OCS more profitable?

Do institutionals & insiders believe in ADAG or OCS?

Do analysts recommend ADAG or OCS?

Which has preferable valuation & earnings, ADAG or OCS?

Does the media refer more to ADAG or OCS?

Summary

How does Adagene compare to Forte Biosciences?

Does the media favor ADAG or FBRX?

Do institutionals and insiders have more ownership in ADAG or FBRX?

Do analysts prefer ADAG or FBRX?

Which has more volatility and risk, ADAG or FBRX?

Is ADAG or FBRX more profitable?

Which has preferable earnings & valuation, ADAG or FBRX?

Summary

How does Adagene compare to Gyre Therapeutics?

Which has more risk & volatility, ADAG or GYRE?

Which has preferable valuation and earnings, ADAG or GYRE?

Do analysts prefer ADAG or GYRE?

Do insiders and institutionals believe in ADAG or GYRE?

Is ADAG or GYRE more profitable?

Does the media favor ADAG or GYRE?

Summary

How does Adagene compare to ARS Pharmaceuticals?

Which has preferable earnings and valuation, SPRY or ADAG?

Do institutionals and insiders believe in SPRY or ADAG?

Do analysts prefer SPRY or ADAG?

Is SPRY or ADAG more profitable?

Does the media prefer SPRY or ADAG?

Which has more risk and volatility, SPRY or ADAG?

Summary

How does Adagene compare to Allogene Therapeutics?

Do insiders and institutionals believe in ALLO or ADAG?

Is ALLO or ADAG more profitable?

Which has better valuation and earnings, ALLO or ADAG?

Does the media prefer ALLO or ADAG?

Which has more volatility and risk, ALLO or ADAG?

Do analysts prefer ALLO or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools